- Home
- MCRB vs DCGO Comparison
MCRB vs DCGO Comparison
Compare MCRB & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- DCGO
- Stock Information
- Founded
- MCRB 2010
- DCGO 2015
- Country
- MCRB United States
- DCGO United States
- Employees
- MCRB N/A
- DCGO N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- DCGO Managed Health Care
- Sector
- MCRB Health Care
- DCGO Health Care
- Exchange
- MCRB Nasdaq
- DCGO Nasdaq
- Market Cap
- MCRB 125.7M
- DCGO 139.7M
- IPO Year
- MCRB 2015
- DCGO N/A
- Fundamental
- Price
- MCRB $19.44
- DCGO $1.72
- Analyst Decision
- MCRB Hold
- DCGO Strong Buy
- Analyst Count
- MCRB 4
- DCGO 4
- Target Price
- MCRB $73.67
- DCGO $3.78
- AVG Volume (30 Days)
- MCRB 126.4K
- DCGO 546.7K
- Earning Date
- MCRB 08-06-2025
- DCGO 08-07-2025
- Dividend Yield
- MCRB N/A
- DCGO N/A
- EPS Growth
- MCRB N/A
- DCGO N/A
- EPS
- MCRB 10.22
- DCGO N/A
- Revenue
- MCRB N/A
- DCGO $435,968,564.00
- Revenue This Year
- MCRB N/A
- DCGO N/A
- Revenue Next Year
- MCRB N/A
- DCGO N/A
- P/E Ratio
- MCRB $1.98
- DCGO N/A
- Revenue Growth
- MCRB N/A
- DCGO N/A
- 52 Week Low
- MCRB $6.53
- DCGO $1.23
- 52 Week High
- MCRB $26.40
- DCGO $5.68
- Technical
- Relative Strength Index (RSI)
- MCRB 69.44
- DCGO 61.01
- Support Level
- MCRB $15.79
- DCGO $1.57
- Resistance Level
- MCRB $18.12
- DCGO $1.72
- Average True Range (ATR)
- MCRB 1.51
- DCGO 0.11
- MACD
- MCRB 0.28
- DCGO 0.02
- Stochastic Oscillator
- MCRB 97.69
- DCGO 86.05
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.